May 2026
1. GIOVANNONI G, Airas L, Bove R, Cutter GR, et al
   Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.
   Lancet. 2026;407:2195-2207.
   

   >> Share

   
   
2. HAUSER SL, Giovannoni G, Montalban X, Oh J, et al
   Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.
   Lancet. 2026;407:2180-2194.
   

   >> Share

   
   
3. SAMARASEKERA U
   Stephen Hauser: transforming treatment for multiple sclerosis.
   Lancet. 2026;407:2163.
   

   >> Share

   
   
4. COCCO E
   Integrating peripheral immune control and brain health in the multiple sclerosis continuum.
   Lancet. 2026;407:2144-2146.
   

   >> Share

   
   October 2025
5. FILIPPI M, Rocca MA
   MS-STAT2: lessons from negative trials in multiple sclerosis.
   Lancet. 2025 Oct 1:S0140-6736(25)01673-3. doi: 10.1016/S0140-6736(25)01673.
   

   >> Share

   
   
6. CHATAWAY J, Williams T, Blackstone J, John N, et al
   Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial.
   Lancet. 2025 Oct 1:S0140-6736(25)01039-6. doi: 10.1016/S0140-6736(25)01039.
   

   >> Share

   
   November 2023
7. JAKIMOVSKI D, Bittner S, Zivadinov R, Morrow SA, et al
   Multiple sclerosis.
   Lancet. 2023 Nov 7:S0140-6736(23)01473-3. doi: 10.1016/S0140-6736(23)01473.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share